ANAB vs PCRX: stock comparison and AI forecast
Anaptysbio, Inc (ANAB) and Pacira Biosciences, Inc. (PCRX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ANAB Anaptysbio, Inc
- Price
- $46.91 -32.8% · 6M
- Market Cap
- $1.40B
- P/E Ratio
- 12.3x
- Size
- small-cap
- AI Forecast
PCRX Pacira Biosciences, Inc.
- Market Cap
- $1.45B
- P/E Ratio
- 125.5x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ANAB and PCRX have similar market capitalizations ($1.40B and $1.45B).
- ANAB trades at 12.3 times trailing earnings, PCRX at 125.5 times.
- ANAB carries 28.95 times debt per unit of equity, against 0.85 times for PCRX.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ANAB | PCRX |
|---|---|---|
| Market Cap | $1.40B | $1.45B |
| P/E Ratio | 12.28x | 125.52x |
| P/B Ratio | 132.49x | 2.16x |
| EPS | $3.82 | $0.29 |
| Book Value/Share | $0.35 | $16.86 |
| Revenue/Share | $8.80 | $18.72 |
| FCF/Share | – | $4.50 |
Profitability & Margins
| Metric | ANAB | PCRX |
|---|---|---|
| ROE | – | 2.2% |
| ROA | – | 1.2% |
| ROIC | 35.3% | 1.8% |
| Gross Margin | – | 79.2% |
| Operating Margin | 33.6% | 2.7% |
| Net Margin | – | 2.0% |
| EBT Margin | 2.3% | 2.4% |
| Tax Rate | -2639.1% | 17.1% |
Financial Health
| Metric | ANAB | PCRX |
|---|---|---|
| Current Ratio | 5.61x | 5.04x |
| Quick Ratio | – | 3.94x |
| D/E Ratio | 28.95x | 0.85x |
| Financial Leverage | 29.95x | 1.85x |
| Interest Coverage | 0.8x | 1.2x |
| Working Capital | $163M | $493M |
Cash Flow
| Metric | ANAB | PCRX |
|---|---|---|
| Operating Cash Flow | -$8M | $188M |
| Free Cash Flow | – | $180M |
| Capital Spending | – | -$8M |
| OCF Growth YoY | – | 39.5% |
| FCF Growth YoY | – | 53.3% |
| FCF/Sales | – | 24.1% |
| CapEx/Sales | – | 1.1% |
Operational Efficiency
| Metric | ANAB | PCRX |
|---|---|---|
| Asset Turnover | 0.83x | 0.60x |
| Receivables Turnover | 10.3x | 5.6x |
| Inventory Turnover | – | 1.1x |
| Fixed Assets Turnover | 2580.1x | 5.7x |
| Days Sales Outstanding | 36 days | 65 days |
| Days Inventory | – | 317 days |
| Payables Period | – | 41 days |
| Cash Conversion Cycle | – | 340 days |
Income Statement
| Metric | ANAB | PCRX |
|---|---|---|
| Total Revenue | $263M | $746M |
| Operating Income | $99M | $20M |
| Net Income | – | $15M |
| R&D Expense | $129M | $122M |
| SG&A Expense | – | $379M |
| Cost of Goods Sold | – | $155M |
Dividend & Shareholder Information
| Metric | ANAB | PCRX |
|---|---|---|
| Shares Outstanding | 30M | 40M |
ANAB vs PCRX: stock comparison and AI forecast
Which is bigger, ANAB or PCRX?
ANAB and PCRX have similar market capitalizations ($1.40B and $1.45B).
Which is cheaper on earnings, ANAB or PCRX?
ANAB trades at 12.3 times trailing earnings, PCRX at 125.5 times.
Which one does Intratio's AI model rank higher, ANAB or PCRX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.